Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.74 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.62 |
| ▸ | ICMT | O60725 | 3/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5066540 | 0.86 | GPR84 (0.65) | MPOGPR84SLC6A4RIPK1GAA | |
| SCHEMBL32684019 | 0.81 | HTR2A (0.60) | MPOSLC6A4ICMTRIPK1GAA | |
| SCHEMBL8088111 | 0.81 | HTR2A (0.60) | MPOSLC6A4ICMTRIPK1GAA | |
| SCHEMBL32684012 | 0.81 | MPO (0.50) | MPOGPR84SLC6A4ICMTGAA | |
| SCHEMBL3611008 | 0.81 | HTR2A (0.60) | MPOICMTGAANPSR1PCSK9 | |
| SCHEMBL26430627 | 0.80 | MPO (0.63) | MPOGPR84SLC6A4RIPK1PCSK9 | |
| Oxalic Acid SCHEMBL2535897 | 0.79 | MPO (0.82) | MPOGPR84SLC6A4NPSR1HTR2A | |
| SCHEMBL18509171 | 0.78 | GPR84 (0.73) | MPOGPR84SLC6A4RIPK1NPSR1 | |
| SCHEMBL5163846 | 0.78 | CSNK2A2 (0.50) | MPOICMTGAANPSR1LMNA | |
| SCHEMBL29005984 | 0.78 | GPR84 (1.00) | MPOGPR84SLC6A4RIPK1PCSK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | claimed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | claimed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | claimed |
| EP-2167077-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008152099-A2 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | MPO 4605/4885GPR84 85/4885SLC6A4 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.